Literature DB >> 14638772

An enzymatically active a domain is required for cholera-like enterotoxins to induce a long-lived blockade on the induction of oral tolerance: new method for screening mucosal adjuvants.

Kenneth C Bagley1, Sayed F Abdelwahab, Robert G Tuskan, George K Lewis.   

Abstract

The cholera-like enterotoxins (CLETS), cholera toxin (CT) and Escherichia coli heat-labile toxin (LT), are powerful mucosal adjuvants. Here we show that these toxins also induce a long-lived blockade (of at least 6 months) on the induction of oral tolerance when they are coadministered with the antigen ovalbumin. Strikingly, only enzymatically active CLETS induced this blockade on the induction of oral tolerance. In this regard, the enzymatically inactive mutants of CT and LT, CTK63 and LTK63, and their recombinant B pentamers, rCTB and rLTB, failed to block the induction of oral tolerance, demonstrating a stringent requirement for an enzymatically active A domain in this phenomenon. Together with the results of other recent studies, these results indicate that the enzymatic activity of CLETS, most likely cyclic AMP elevation, is responsible for their adjuvant effects. The results of this study also indicate that measuring the ability of putative mucosal adjuvants to block the induction of oral tolerance may be a superior method for measuring mucosal adjuvanticity.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14638772      PMCID: PMC308947          DOI: 10.1128/IAI.71.12.6850-6856.2003

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  40 in total

1.  Immunogenicity of DNA vaccines that direct the coincident expression of the 120 kDa glycoprotein of human immunodeficiency virus and the catalytic domain of cholera toxin.

Authors:  K C Bagley; M T Shata; D Y Onyabe; A L DeVico; T R Fouts; G K Lewis; D M Hone
Journal:  Vaccine       Date:  2003-07-04       Impact factor: 3.641

2.  Cholera toxin: interaction of subunits with ganglioside GM1.

Authors: 
Journal:  Science       Date:  1974-02-15       Impact factor: 47.728

3.  Size and structure of the cholera toxin molecule and its subunits.

Authors:  N Ohtomo; T Muraoka; A Tashiro; Y Zinnaka; K Amako
Journal:  J Infect Dis       Date:  1976-03       Impact factor: 5.226

Review 4.  Oral tolerance.

Authors:  T B Tomasi
Journal:  Transplantation       Date:  1980-05       Impact factor: 4.939

5.  Strong adjuvant properties of cholera toxin on gut mucosal immune responses to orally presented antigens.

Authors:  N Lycke; J Holmgren
Journal:  Immunology       Date:  1986-10       Impact factor: 7.397

6.  Effectiveness of cholera toxin B subunit as an adjuvant for nasal influenza vaccination despite pre-existing immunity to CTB.

Authors:  S Tamura; H Funato; T Nagamine; C Aizawa; T Kurata
Journal:  Vaccine       Date:  1989-12       Impact factor: 3.641

7.  Mechanism of adenylate cyclase activation by cholera toxin: inhibition of GTP hydrolysis at the regulatory site.

Authors:  D Cassel; Z Selinger
Journal:  Proc Natl Acad Sci U S A       Date:  1977-08       Impact factor: 11.205

8.  Long-term cholera antitoxin memory in the gut can be triggered to antibody formation associated with protection within hours of an oral challenge immunization.

Authors:  N Lycke; J Holmgren
Journal:  Scand J Immunol       Date:  1987-04       Impact factor: 3.487

9.  Cholera toxin and heat-labile enterotoxin activate human monocyte-derived dendritic cells and dominantly inhibit cytokine production through a cyclic AMP-dependent pathway.

Authors:  Kenneth C Bagley; Sayed F Abdelwahab; Robert G Tuskan; Timothy R Fouts; George K Lewis
Journal:  Infect Immun       Date:  2002-10       Impact factor: 3.441

10.  Comparison of the carbohydrate-binding specificities of cholera toxin and Escherichia coli heat-labile enterotoxins LTh-I, LT-IIa, and LT-IIb.

Authors:  S Fukuta; J L Magnani; E M Twiddy; R K Holmes; V Ginsburg
Journal:  Infect Immun       Date:  1988-07       Impact factor: 3.441

View more
  6 in total

1.  Mucosal immunization with a Staphylococcus aureus IsdA-cholera toxin A2/B chimera induces antigen-specific Th2-type responses in mice.

Authors:  Britni M Arlian; Juliette K Tinker
Journal:  Clin Vaccine Immunol       Date:  2011-07-06

2.  Cholera toxin indirectly activates human monocyte-derived dendritic cells in vitro through the production of soluble factors, including prostaglandin E(2) and nitric oxide.

Authors:  Kenneth C Bagley; Sayed F Abdelwahab; Robert G Tuskan; George K Lewis
Journal:  Clin Vaccine Immunol       Date:  2006-01

3.  Adjuvant activity of the catalytic A1 domain of cholera toxin for retroviral antigens delivered by GeneGun.

Authors:  Kenneth C Bagley; George K Lewis; Timothy R Fouts
Journal:  Clin Vaccine Immunol       Date:  2011-04-20

4.  Induction and recall of immune memory by mucosal immunization with a non-toxic recombinant enterotoxin-based chimeric protein.

Authors:  Christine M Gockel; Michael W Russell
Journal:  Immunology       Date:  2005-12       Impact factor: 7.397

5.  Bacterial Toxin Fusion Proteins Elicit Mucosal Immunity against a Foot-and-Mouth Disease Virus Antigen When Administered Intranasally to Guinea Pigs.

Authors:  Sreerupa Challa; Steven M Szczepanek; Debra Rood; Roger W Barrette; Lawrence K Silbart
Journal:  Adv Virol       Date:  2011-09-22

6.  The catalytic A1 domains of cholera toxin and heat-labile enterotoxin are potent DNA adjuvants that evoke mixed Th1/Th17 cellular immune responses.

Authors:  Kenneth Bagley; Rong Xu; Ayuko Ota-Setlik; Michael Egan; Jennifer Schwartz; Timothy Fouts
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.